2012 represents a period with robust news flow for emerging immuno-oncology companies
To Partner, or Not to Partner: That is the Question
March 10, 2011 By 2 Comments
Traditional wisdom holds that biotechnology companies benefit from collaborations with their larger pharmaceutical peers, which can help validate a company’s technology, provide capital to help fund clinical development, and enable access to experienced clinical, regulatory and commercial infrastructure. While this was certainly true in the early days of biotechnology, the industry has now matured – [...]
Investment Opportunities with Five Frontline Therapies for AML
September 6, 2010 By 2 Comments
Acute myelogenous leukemia [AML] is a fast-growing cancer of the blood and bone marrow. Unformed cells called myeloblasts, or “blasts,” reside in the bone marrow and normally become a particular kind of cell – a white blood cell, red blood cell, or platelet. In AML, abnormal blasts produce white blood cells that do not function [...]
Stem Cell Competition Heating Up
August 23, 2010 By 2 Comments
According to the National Institutes of Health’s [NIH] stem cell primer, stem cells have the ability to develop into many different cell types in the body during early life and growth. In many tissues they serve as an internal repair system, dividing essentially without limit to replenish other cells. When a stem cell divides, each [...]
Gut Check Time for GVHD Companies: BMT Tandem Meetings Review
February 28, 2010 By 2 Comments
The 2010 BMT Tandem Meetings were held in Orlando, Florida this past week [February 24-28, 2010]. Considered the premier event for hematopoietic cell transplantation [HCT] and cellular therapy, the annual event attracts more than 2,500 clinicians, transplant nurses, clinical research professionals, data managers, pharmacists, center administrators and mid-level practitioners. With more than 200 abstracts being [...]
Follow MD Becker Partners